Monocyte to high-density lipoprotein cholesterol ratio predicts poor outcomes in ischaemic heart failure patients combined with diabetes: a retrospective study

Table 4 The interaction effects between MHR and MACE in patients with hypercholesterolemia or no hypercholesterolemia

Hypercholesterolemia	HR (95% CI)	P Value	No hypercholesterolemia	HR (95% CI)	P Value	P for interaction
Model 1			Model 1			0.867
Quartile 1: MHR < 0.33	Reference		Quartile 1: MHR < 0.33	Reference
Quartile 2: 0.33 ≤ MHR < 0.46	1.45 (1.00–2.09)	0.051	Quartile 2: 0.33 ≤ MHR < 0.46	2.46 (1.28–4.71)	0.007
Quartile 3: 0.46 ≤ MHR < 0.62	1.73 (1.20–2.47)	0.003	Quartile 3: 0.46 ≤ MHR < 0.62	3.11 (1.65–5.86)	< 0.001
Quartile 4: MHR ≥ 0.62	2.66 (1.90–3.72)	< 0.001	Quartile 4: MHR ≥ 0.62	3.19 (1.66–6.11)	< 0.001
Continuous	1.37 (0.67–2.82)	0.389	Continuous	2.94 (1.51–5.73)	0.001
Model 2			Model 2			0.963
Quartile 1: MHR < 0.33	Reference		Quartile 1: MHR < 0.33	Reference
Quartile 2: 0.33 ≤ MHR < 0.46	1.48 (1.02–2.16)	0.041	Quartile 2: 0.33 ≤ MHR < 0.46	2.23 (1.15–4.31)	0.017
Quartile 3: 0.46 ≤ MHR < 0.62	1.78 (1.24–2.57)	0.002	Quartile 3: 0.46 ≤ MHR < 0.62	2.82 (1.45–5.46)	0.002
Quartile 4: MHR ≥ 0.62	2.74 (1.94–3.89)	< 0.001	Quartile 4: MHR ≥ 0.62	2.93 (1.52–5.65)	0.001
Continuous	1.33 (0.65–2.72)	0.431	Continuous	2.55 (1.30–5.02)	0.007
Model 3			Model 3			0.803
Quartile 1: MHR < 0.33	Reference		Quartile 1: MHR < 0.33	Reference
Quartile 2: 0.33 ≤ MHR < 0.46	1.46 (0.99–2.14)	0.053	Quartile 2: 0.33 ≤ MHR < 0.46	2.26 (1.09–4.69)	0.029
Quartile 3: 0.46 ≤ MHR < 0.62	1.61 (1.11–2.33)	0.011	Quartile 3: 0.46 ≤ MHR < 0.62	3.38 (1.62–7.09)	0.001
Quartile 4: MHR ≥ 0.62	2.17 (1.50–3.13)	< 0.001	Quartile 4: MHR ≥ 0.62	3.29 (1.49–7.27)	0.003
Continuous	1.17 (0.55–2.50)	0.687	Continuous	1.86 (0.79–4.35)	0.153

Models were derived from Cox proportional hazards regression analysis. Model 1: unadjusted. Model 2: adjusted for age, sex. Model 3: adjusted for age, sex, heart rate, body mass index, LVDd, LM disease, chronic total occlusion, diffuse lesion, target vessel of LM, complete revascularization, number of stents, total bilirubin, direct bilirubin, TC, triglyceride glucose, platelet, ARB, sacubitril/valsartan, metformin, SGLT2 inhibitor
HR, hazards ratio; CI, confidence interval; MACE, major adverse cardiovascular events; MHR, monocyte to high-density lipoprotein cholesterol ratio; MI, myocardial infarction; LVDd, left ventricular end diastolic diameter; LM, left main artery; TC, total cholesterol; ARB, angiotensin receptor blocker; SGLT2, sodium-glucose cotransporter 2

ISSN: 2047-783X